Startup profile · funding coverage
Biomatter funding, valuation and investors
Vilnius biotech enterprise designing custom enzymes with generative models and laboratory testing.
Verified company research · funding, investors and latest developments
Keep track of Biomatter
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series A
$18M new funding · November 12, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$18M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series a · Vilnius, Lithuania
Investors in latest funding
Lead: Astanor
Other: UVC Partners , Inventure , Metaplanet
Overview
Biomatter is a Vilnius, Lithuania company founded in 2018. A Biomatter-issued Business Wire/EQS release dated November 12, 2026 confirms an oversubscribed $18M Series A led by Astanor with returning UVC Partners, Inventure and Metaplanet. UVC/UnternehmerTUM confirmed a separate €6.5M seed co-led by UVC Partners and Inventure on August 5, 2024.
Biomatter reports 25+ enterprise clients and 50+ custom enzymes delivered, naming AstraZeneca, BASF, Kirin, Neogen, Sanofi and Tereos; Thermo Fisher's SuperScript V is a named example. The 2,000-square-metre Vilnius lab is scheduled for 2027, not existing capacity. Customer figures and claimed performance are issuer-supplied, not independent sales verification.
Sources: https://www.businesswire.com/news/home/20261111065246/en/ ; https://webdisclosure.fr/press-release/biomatter-etr-biomatter-raises-18m-series-a-to-scale-its-ai-powered-enzyme-design-for-global-industry-leaders-W3MF3QB2F1D ; https://www.unternehmertum.de/presse/biomatter-erhaelt-6-5-millionen-euro-fuer-die-entwicklung-neuartiger-enzyme-mit-seiner-generativen-ki-plattform/
Why Biomatter is interesting
$18M November 2026 Series A led by Astanor after a separate €6.5M seed in 2024. Company reports 25+ customer companies, 50+ delivered enzymes and a production reagent case; these are issuer statements, not audited revenue.
Product & use cases
Illustrative B2B buyer journey, NOT hands-on testing: 1) describe desired chemistry and stability/yield constraints; 2) define enzyme specifications; 3) generate candidate protein sequences using Intelligent Architecture; 4) physically test and iterate variants in laboratory; 5) deliver validated candidates for customer qualification and manufacturing. Current customer-specific pricing, selection success rates, IP licences and production costs are undisclosed. Thermo Fisher SuperScript V oxidation resistance is a company-reported example; a proposed 2027 lab is future capacity.
- Diagnostics/RNA research: design more stable reverse-transcriptase reagent for shipping and storage.
- Biomanufacturing: test enzymes requiring fewer expensive chemical cofactors.
- Food/chemical manufacturing: contract for tailor-made catalysts validated in lab before production use.
Key facts
- Nov 12 2026 $18M Series A led by Astanor.
- Aug 5 2024 distinct €6.5M seed co-led UVC and Inventure.
- Issuer says 25+ enterprise clients and 50+ custom enzymes delivered; proposed 2027 Vilnius lab.
Funding history (newest first)
Series A
2026-11-12 $18M new funding- Astanor (lead)
- UVC Partners (participant)
- Inventure (participant)
- Metaplanet (participant)
Source: Read source · businesswire.com
Seed
2024-08-05 €6.5M new funding- UVC Partners (lead)
- Inventure (lead)
- Practica Capital (participant)
- Metaplanet (participant)
Source: Read source · unternehmertum.de
Competitive landscape
Edge: Proprietary wet-lab data combined with AI sequence generation. Qualification, reproducibility, IP allocation, opaque contract pricing, real margins and bottlenecks remain open questions.
-
Codexis alternative
Industrial enzyme engineering and delivery.
-
Cradle adjacent
AI protein-design tools with a different engagement model.
-
Directed evolution incumbent
Conventional lab mutagenesis and screening.
Market / IPO context
Editorial / static context — not a live quote.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.